Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Investor Day (May 2023)
10 slides from Orion Oyj Class A's investor day presentation, May 25, 2023
Slide 1: Generics and Consumer Health
Generics and Consumer Health Satu Ahomäki, Senior Vice President
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Overview of Generics and Consumer Health
Overview of Generics and Consumer Health 600 557 500 -8% • Our purpose is to create everybody EUR million 400 300 Q1'22 an access to affordable quality medicines, and help 200 145 134 Q1'23 individuals to promote their health 2022 100 • Sales decrease compared to last year due to 0 declining sales i
Slide 4: Gx and Consumer Health have been a bedrock of Orion for years
Gx and Consumer Health have been a bedrock of Orion for years Orion market leader in Finland Re-imbursement system change in Finland 1-12/2022 Orion’s market share Market position 600 70% 500 60% Total sales of human 11% pharmaceuticals #1 400 50% MEUR 300 40% Reference priced prescription 200 30% d
Slide 5: Growth requires “Think Bigger” mindset
Growth requires “Think Bigger” mindset Cherish the current business Limited growth opportunities for current product portfolio and geographic presence Growth from new products to wider sales territories In-organic growth to expand presence and >50% Of sales from Finland portfolio to wider territorie
Slide 6: Generics and Consumer Health – product segments
Generics and Consumer Health – product segments Generic prescription drugs – Generic prescription drugs – hospital use retail use Consumer Health • Simdax® and Dexdor® form a • Sales in few key countries in • Strong portfolio in Finland foundation of the segment Nordics and Eastern Europe are • Cons
Slide 7: Strategic partnership with Amneal creates a significant growth opportunity for GxCH business
Strategic partnership with Amneal creates a significant growth opportunity for GxCH business • Orion has an exclusive license to commercialise Amneal’s generic products in Europe, Australia and New Zealand • The initial portfolio will include a mix of generic products commercially available in the U
Slide 8: Building blocks for growth
Building blocks for growth Vigorous Improved Territorial product flow competitiviness expansion Continuous renewing and management of product portfolio is required due to the dynamic nature of the business 8 CMD 25 May 2023 © Orion Corporation
Slide 9: Key takeaways
Key takeaways 1. Unique position in Finland 2. Geographic expansion for further growth 3. Focus on complex generics and value-add products 9 CMD 25 May 2023 © Orion Corporation
Slide 10: Slide 10